WT1

Chr 11ADSomatic

WT1 transcription factor

Transcription factor that plays an important role in cellular development and cell survival (PubMed:7862533). Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3' (PubMed:17716689, PubMed:25258363, PubMed:7862533). Regulates the expression of numerous target genes, including EPO. Plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. Function may be isoform-specific: isoforms lacking the KTS motif may act as transcription factors (PubMed:15520190). Isoforms containing the KTS motif may bind mRNA and play a role in mRNA metabolism or splicing (PubMed:16934801). Isoform 1 has lower affinity for DNA, and can bind RNA (PubMed:19123921)

Primary Disease Associations & Inheritance

Wilms tumor, type 1MIM #194070
ADSomatic
Wilms tumorMIM #194070
ADSomatic
Wilms tumor, somaticMIM #194070
Denys-Drash syndromeMIM #194080
ADSomatic
Frasier syndromeMIM #136680
ADSomatic
Meacham syndromeMIM #608978
AD
Mesothelioma, somaticMIM #156240
Nephrotic syndrome, type 4MIM #256370
AD
Wilms tumor, type 1MIM #194070
ADSomatic
UniProtWilms tumor 1
UniProtMesothelioma, malignant
0
ClinVar variants
0
Pathogenic / LP
1.00
pLI score· haploinsufficient
12
Active trials
Clinical SummaryWT1
Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available
Some data sources returned errors (2)

ncbi: Error: NCBI fetch failed: 429 https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi

clinvarCount: Error: NCBI fetch failed: 429 https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.25LOEUF
pLI 0.996
Z-score 4.31
OE 0.08 (0.030.25)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
1.78Z-score
OE missense 0.70 (0.630.79)
201 obs / 285.7 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.08 (0.030.25)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.70 (0.630.79)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.00
01.21.6
LoF obs/exp: 2 / 25.5Missense obs/exp: 201 / 285.7Syn Z: -0.03

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

WT1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

WT1-related Wilms tumour

definitive
ADLoss Of FunctionAbsent Gene Product
Cancer
G2P ↗

WT1-related Denys-Drash syndrome

definitive
ADDominant NegativeAltered Gene Product Structure
Dev. Disorders
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

2 OMIM entries

WILMS TUMOR 1; WT1
MIM #194070 · #

Wilms tumor, type 1

MIM #194070

Molecular basis of disorder known

Autosomal dominantSomatic mutation

Wilms tumor

MIM #194070

Molecular basis of disorder known

Autosomal dominantSomatic mutation

Wilms tumor, somatic

MIM #194070

Molecular basis of disorder known

Denys-Drash syndrome

MIM #194080

Molecular basis of disorder known

Autosomal dominantSomatic mutation

Frasier syndrome

MIM #136680

Molecular basis of disorder known

Autosomal dominantSomatic mutation

Meacham syndrome

MIM #608978

Molecular basis of disorder known

Autosomal dominant

Mesothelioma, somatic

MIM #156240

Molecular basis of disorder known

Nephrotic syndrome, type 4

MIM #256370

Molecular basis of disorder known

Autosomal dominant

Wilms tumor, type 1

MIM #194070

Molecular basis of disorder known

Autosomal dominantSomatic mutation

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Pleuropulmonary BlastomaCystic NephromaOvarian Sertoli-Leydig Cell Tumors

DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

RECRUITING
NCT01247597National Cancer Institute (NCI)Started 2011-02-13
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

ACTIVE NOT RECRUITING
NCT03155620Phase PHASE2National Cancer Institute (NCI)Started 2017-07-31
Biopsy ProcedureBiospecimen CollectionBone Marrow Aspiration and Biopsy
Adult Cystic NephromaAnaplastic Kidney Wilms TumorAngiolipoma

Study of Kidney Tumors in Younger Patients

ACTIVE NOT RECRUITING
NCT00898365Children's Oncology GroupStarted 2006-02-27
Cytology Specimen Collection ProcedureLaboratory Biomarker Analysis
HepatoblastomaHepatocellular CarcinomaWilms Tumor

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

RECRUITING
NCT06198296Phase PHASE1Baylor College of MedicineStarted 2025-06-10
21.15.GPC3-CAR T cells
Ewing SarcomaDesmoplastic Small Round Cell TumorPediatric Cancer

Lurbinectedin in FET-Fused Tumors

RECRUITING
NCT05918640Phase PHASE1, PHASE2Children's Hospital of PhiladelphiaStarted 2023-07-27
Lurbinectedin
Solid TumorsCNS Tumors

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

ACTIVE NOT RECRUITING
NCT02650401Phase PHASE1, PHASE2Hoffmann-La RocheStarted 2016-05-03
Entrectinib
Acute LeukemiaAdenomatous PolyposisAdrenocortical Carcinoma

Familial Investigations of Childhood Cancer Predisposition

RECRUITING
NCT03050268St. Jude Children's Research HospitalStarted 2017-04-06
Acute Myeloid LeukemiaMyelodysplastic Syndrome

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

ACTIVE NOT RECRUITING
NCT02494167Phase PHASE1Baylor College of MedicineStarted 2016-02
MultiTAA-specific T cells
Diabetic Kidney Disease

Role of Finerenone in African American Veterans With Diabetic Kidney Disease

NOT YET RECRUITING
NCT07155694Phase PHASE4Washington D.C. Veterans Affairs Medical CenterStarted 2025-09
Finerenone 10 MGEmpagliflozin 10 MG
Liver Cell CarcinomaSolid TumorWilms Tumor

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

ACTIVE NOT RECRUITING
NCT05103631Phase PHASE1Baylor College of MedicineStarted 2021-06-17
CATCH T cells
Desmoplastic Small Round Cell Tumor

Clinical Study in Patients With DSRCT

RECRUITING
NCT07328425Phase PHASE2Italian Sarcoma GroupStarted 2025-11-21
LurbinectedinIrinotecan
Pleuropulmonary BlastomaSertoli-Leydig Cell TumorDICER1 Syndrome

International PPB/DICER1 Registry

RECRUITING
NCT03382158Children's Hospitals and Clinics of MinnesotaStarted 2016-12-06